Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
January 30th, 2009
AcelRx Pharmaceuticals, Inc., an emerging specialty pharmaceutical company focused on the treatment of intermittent and acute medical conditions with an initial emphasis on pain management, announced positive results from a Phase 1 clinical study evaluating the safety, tolerability and efficacy of the company's proprietary sublingual sufentanil (opioid) and triazolam (benzodiazepine) NanoTab(TM) combination product candidate (ARX-03). The product is designed to address the current unmet need for a non-invasive product to provide sedation and analgesia for an increasing number of office-based procedures. The study demonstrated that administration of ARX-03 resulted in a...
Source: Health Business Week (2009-01-30)
|
